• FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation 
    Thursday, October 30, 2025 from ESMO News
  • “Immortal” flatworm rewrites the science of healing
    Wednesday, October 29, 2025 from Pancreatic Cancer News -- ScienceDaily
    Flatworms can rebuild themselves from just a small fragment, and now scientists know why. Their stem cells ignore nearby instructions and respond to long-distance signals from other tissues. This discovery turns old stem cell theories...
  • Experts consider ‘targeted’ prostate cancer screening to reduce UK deaths
    Wednesday, October 29, 2025 from Cancer | The Guardian
    New study found screening can reduce deaths by 13% but that overdiagnosis and subsequent overtreatment remain concerns Prostate cancer screening can reduce deaths by 13%, a study suggests. Cancer screening experts are assessing whether...
  • FDA aims to accelerate biosimilar development as way to reduce drug costs
    Wednesday, October 29, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    The FDA today unveiled a plan to accelerate development of biosimilars in hopes of significantly reducing drug costs in the United States. The agency issued draft guidance that would simplify the study of biosimilars and reduce what...
  • Q&A: Evidence-based strategies for preventing, treating chemotherapy-induced hair loss
    Wednesday, October 29, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    Of the 2.3 million women diagnosed annually with breast cancer worldwide, research shows more than half report having psychological stress due to chemotherapy-induced hair loss. Data from a 2014 study published in the Journal of the...
  • Adenomas, immune checkpoint inhibitor colitis warrant colonoscopy
    Wednesday, October 29, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    PHOENIX — Adult patients with cancer who had adenomas at baseline and immune checkpoint inhibitor-mediated diarrhea and colitis faced a greater risk for further colon adenoma development, according to study data. Findings presented at...
  • VIDEO: Experts move toward viewing follicular lymphoma as ‘potentially a curable disease’
    Wednesday, October 29, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    In this video, Leo I. Gordon, MD, FACP, discusses the growing view that follicular lymphoma could be viewed as “curable.” The position that follicular lymphoma is considered a chronic disease, but not necessarily a curable disease, is...
  • VIDEO: Considerations, challenges associated with extranodal marginal zone lymphoma
    Wednesday, October 29, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    In this video, Leo I. Gordon, MD, FACP, discusses highlights from his presentation on extranodal marginal zone lymphomas at the Lymphoma Leukemia & Myeloma Congress. “These marginal zone lymphomas are antigen driven and sometimes...
  • ‘A big deal’: Discovery of new genetic link to osteosarcoma opens ‘window of opportunity’
    Wednesday, October 29, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    Researchers have discovered a new genetic link to the most common type of bone cancer among children and young adults. Inherited mutations in the SMARCAL1 gene are significantly associated with osteosarcoma risk, an analysis of nearly...
  • Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC 
    Wednesday, October 29, 2025 from ESMO News
    Findings from the cohorts 1 and 2 of the TUXEDO-3 study
  • Rheumatic disease incurs higher financial costs than cancer
    Tuesday, October 28, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    CHICAGO — Chronic rheumatic diseases may impose greater long-term financial burdens than cancer, particularly for younger adults, according to data presented at ACR Convergence 2025. “Financial toxicity is a well-recognized problem in...
  • Tumor board aims to treat cancer pain with same urgency as the malignancy
    Tuesday, October 28, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    Tumor boards are an invaluable tool to share knowledge and ensure optimal treatment for people with cancer. The conversations that occurred in the hallways outside those disease-focused panels, however, prompted Alan Alper Sag, MD, FSIR,...
  • Big-brand authors: it isn’t in our genes | Brief letters
    Tuesday, October 28, 2025 from Cancer | The Guardian
    Book marketing | Labour’s moral exhaustion | Nitrite-free meat | Praise for the readers’ editor’s team | Rewind to racist language Nigel Newton asserts that “We are programmed deep in our DNA to be comforted by the authority and the...
  • Steroids for arthritis due to ICI use may not impact cancer
    Tuesday, October 28, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    CHICAGO — The use of glucocorticoids, at doses prescribed by rheumatologists, for inflammatory arthritis resulting from checkpoint inhibitors may not substantially impact cancer outcomes, according to data presented at ACR Convergence...
  • [Articles] Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
    Tuesday, October 28, 2025 from The Lancet Oncology
    Dual inhibition of CDK4 and CDK6 and the androgen receptor pathway with abemaciclib plus abiraterone did not improve radiographic progression-free survival compared with abiraterone alone in the CYCLONE 2 study population with mCRPC....
  • [Articles] Physical examinations and whole-body imaging versus physical examinations alone during follow-up after radical surgery of stage IIB–C and III cutaneous malignant melanoma (TRIM): an interim analysis of a multicentre, randomised, phase 3 trial i
    Tuesday, October 28, 2025 from The Lancet Oncology
    This interim analysis indicated that there is no benefit from imaging in the follow-up programme for individuals with high-risk cutaneous malignant melanoma. However, only a few participants have completed the follow-up time of 5 years,...
  • [Review] Tumour-infiltrating lymphocyte therapy comes of age in the era of genetic engineering
    Tuesday, October 28, 2025 from The Lancet Oncology
    Advances in cancer immunotherapy from immune checkpoint modulation to adoptive cell transfer of tumour-infiltrating lymphocytes (TILs) have greatly improved outcomes for patients with advanced cancers, particularly metastatic melanoma....
  • [Policy Review] Measurable residual disease-guided interventions in patients with acute myeloid leukaemia undergoing allogeneic haematopoietic cell transplantation: best practice recommendations from the European Society for Blood and Marrow Transplantati
    Tuesday, October 28, 2025 from The Lancet Oncology
    Measurable residual disease (MRD) is a key predictor of relapse, the primary cause of treatment failure after allogeneic haematopoietic cell transplantation (allo-HCT) in acute myeloid leukaemia. This Policy Review, based on guidance...
  • [Policy Review] Artificial Intelligence for Response Assessment in Pediatric Neuro-Oncology (AI-RAPNO), part 1: review of the current state of the art
    Tuesday, October 28, 2025 from The Lancet Oncology
    Artificial intelligence (AI) has the potential to enable more precise, efficient, and reproducible interpretation of medical imaging data to improve patient care in paediatric neuro-oncology. Paediatric brain tumours present distinct...
  • [Policy Review] Artificial Intelligence for Response Assessment in Pediatric Neuro-Oncology (AI-RAPNO), part 2: challenges, opportunities, and recommendations for clinical translation
    Tuesday, October 28, 2025 from The Lancet Oncology
    The Response Assessment in Pediatric Neuro-Oncology (RAPNO) criteria provide an important framework for evaluating treatment efficacy and tumour progression in clinical studies of paediatric brain tumours. As artificial intelligence (AI)...
  • [Clinical Picture] A red patch on the palate
    Tuesday, October 28, 2025 from The Lancet Oncology
    A 62-year-old woman with Behçet's syndrome presented to the Department of Oral Medicine at Institut Universitaire du cancer Toulouse-Oncopole (Toulouse, France) in May, 2025, following an incidental discovery of a palatal lesion during a...
  • [Comment] CYCLONE 2: no impact on prostate cancer forecast
    Tuesday, October 28, 2025 from The Lancet Oncology
    Androgen receptor pathway inhibitors (ARPIs) in combination with androgen deprivation therapy (ADT) represent the foundation of treatment for both metastatic castration-sensitive prostate cancer (mCSPC) and metastatic...
  • [Correspondence] PSMA-TTV as a point-of-care selector
    Tuesday, October 28, 2025 from The Lancet Oncology
    In The Lancet Oncology, Louise Emmett and colleagues1 present an elegant prespecified substudy from the ENZA-p trial that shows that baseline prostate-specific membrane antigen (PSMA)-PET total tumour volume (PSMA-TTV) is not only...
  • [Correspondence] It takes two to tango: importance of oestrogen receptor and progesterone receptor in endometrial cancer
    Tuesday, October 28, 2025 from The Lancet Oncology
    We congratulate Nicole Concin and colleagues with the effort put into the updated ESGO–ESTRO–ESP guidelines.1 Although we support the integration of oestrogen receptor status in the guideline, we wonder why progesterone receptor...
  • [Correspondence] It takes two to tango: importance of oestrogen receptor and progesterone receptor in endometrial cancer – Authors' reply
    Tuesday, October 28, 2025 from The Lancet Oncology
    We thank Vrede and colleagues for their interest in the ESGO–ESTRO–ESP guideline update1 and their comments regarding progesterone receptor immunohistochemistry.
  • [Correspondence] Unadjusted external controls and endpoint selection in Chinese cancer drug trials
    Tuesday, October 28, 2025 from The Lancet Oncology
    I read with interest, the Article by Yichen Zhang and colleagues,1 which presents an important retrospective evaluation of the evidential standards underpinning cancer drug approvals in China between 2017 and 2021. Although the study...
  • [Corrections] Correction to Lancet Oncol 2024; 25: e363–73
    Tuesday, October 28, 2025 from The Lancet Oncology
    Aggarwal A, Simcock R, Price P, et al. NHS cancer services and systems—ten pressure points a UK cancer control plan needs to address. Lancet Oncol 2024; 25: e363–73—In this Policy Review, the second sentence in paragraph 4 of the...
  • [Corrections] Correction to Lancet Oncol 2024; 25: 1337–46
    Tuesday, October 28, 2025 from The Lancet Oncology
    Dawson LA, Ringash J, Fairchild A, et al. Palliative radiotherapy versus best supportive care in patients with painful hepatic cancer (CCTG HE1): a multicentre, open-label, randomised, controlled, phase 3 study. Lancet Oncol 2024; 25:...
  • [Corrections] Correction to Lancet Oncol 2025; 26: 548–49
    Tuesday, October 28, 2025 from The Lancet Oncology
    Turner MC, Godderis L, Guénel P, et al. Carcinogenicity of automotive gasoline and some oxygenated gasoline additives. Lancet Oncol 2025; 26: 548–49—In the Declaration of interests section, statements have been corrected for Jorunn...
  • [Perspectives] Subcutaneous immunotherapy—a wolf in sheep's clothing?
    Tuesday, October 28, 2025 from The Lancet Oncology
    Over the past decade, subcutaneous formulations of anticancer drugs—originally administered intravenously—have been increasingly developed and subsequently approved by the US Food and Drug Administration (FDA). This new route of...
  • [Perspectives] Abdominal shielding not recommended for diagnostic imaging with ionising radiation during pregnancy
    Tuesday, October 28, 2025 from The Lancet Oncology
    In part due to its rare occurrence, cancer during pregnancy poses unique challenges that require careful consideration of both maternal and fetal health. For the best possible outcome for both mother and child, management during...
  • [Articles] Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small-cell lung cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial
    Tuesday, October 28, 2025 from The Lancet Oncology
    HER3-DXd showed promising clinical activity in patients with advanced NSCLC and active brain metastases, and could represent a novel treatment option in this setting.
  • [Articles] Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of breast cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial
    Tuesday, October 28, 2025 from The Lancet Oncology
    HER3-DXd showed promising clinical activity in patients with metastatic breast cancer and active brain metastases, and could offer a novel therapeutic option in this setting.
  • [Editorial] International funding for cancer care: a shared responsibility
    Tuesday, October 28, 2025 from The Lancet Oncology
    A side event held by the Bloomberg New Economy International Cancer Coalition and American Society of Clinical Oncology at the 2025 UN General Assembly in New York, New York, USA, saw the launch of the Global Cancer Financing Platform,...
  • [Comment] Systemic therapy for brain metastases: a changing landscape
    Tuesday, October 28, 2025 from The Lancet Oncology
    In addition to next generation small molecule tyrosine-kinase inhibitors,1,2 large molecular weight antibody–drug conjugates (ADCs) have shown CNS-specific activity, penetrating a blood–brain barrier that is disrupted by local therapies,...
  • VIDEO: ‘Practice-affirming’ data favor osimertinib in advanced lung cancer with progression
    Tuesday, October 28, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    In this video, Charu Aggarwal, MD, MPH, the Leslye M. Heisler Professor for Lung Cancer Excellence at University of Pennsylvania Perelman School of Medicine, reviews recent results from the COMPEL trial. The randomized, double-blinded...
  • Arthritis arising from immune checkpoint therapy distinct from RA
    Tuesday, October 28, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    CHICAGO — Inflammatory arthritis resulting from immune checkpoint inhibitor use is immunologically unique and likely driven by T cells rather than autoantibodies, according to data presented at ACR Convergence 2025. “Inflammatory...
  • Scientists discover COVID mRNA vaccines boost cancer survival
    Tuesday, October 28, 2025 from Cancer News -- ScienceDaily
    Researchers found that COVID-19 mRNA vaccines significantly increased survival in lung and skin cancer patients undergoing immunotherapy. The vaccine appears to prime the immune system in a powerful, nonspecific way, enhancing cancer...
  • Positive interval FIT after colonoscopy highlights need for ‘adequate follow-up’
    Tuesday, October 28, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    PHOENIX — Interval fecal immunochemical testing was positive in up to 17% of patients after colonoscopy regardless of polypectomy, underscoring subsequent colonoscopy needs, according to a study presented at ACG Annual Scientific...
  • Rectal bleeding strong colorectal cancer predictor in younger adults
    Tuesday, October 28, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    Adults aged younger than 50 years who underwent a colonoscopy for rectal bleeding were much more likely to have colorectal cancer, according to data presented at the American College of Surgeons Clinical Congress. “Many of the...
  • Opioid prescribing down among patients with cancer without pain
    Tuesday, October 28, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    Although opioids are “necessary” for cancer care and prescribing is declining over time, clinicians appear to be using their clinical judgment on when to prescribe them. A retrospective analysis of more than 10,000 patients with cancer...
  • EMA Recommends Extension of Indications for Sugemalimab  
    Tuesday, October 28, 2025 from ESMO News
    New indication concerns monotherapy for the treatment of unresectable stage III NSCLC with no genomic alterations  
  • Low alcohol use accounts for thousands of cancer diagnoses
    Monday, October 27, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    Approximately 5,000 breast cancer cases among women each year could be attributed to consuming even one alcoholic drink per day. Low alcohol consumption could account for thousands of colorectal cancer and oral and pharyngeal cancer...
  • Latino patients face greater barriers to timely melanoma care
    Monday, October 27, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    Latino patients face multiple obstacles to proper melanoma care, including language barriers and untimely referrals, according to a study. Compared with white patients, Latino patients are more commonly diagnosed with advanced melanoma...
  • Scientists turn “junk DNA” into a powerful weapon against cancer
    Monday, October 27, 2025 from Cancer News -- ScienceDaily
    King’s College London researchers discovered that parts of our DNA once thought to be “junk” can actually help destroy cancer cells. In some blood cancers, damaged genes trigger chaos in these DNA segments, leaving cancer cells...
  • Poor dental health may increase risk for pancreatic cancer
    Monday, October 27, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    Routine dental hygiene could significantly lower risk for pancreatic cancer. Researchers identified 27 oral bacteria and fungi associated with the malignancy. The combined effect of those microbes on pancreatic cancer risk is greater...
  • VIDEO: Ivonescimab plus chemotherapy confers benefit in EGFR-positive NSCLC
    Monday, October 27, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    In this video, Charu Aggarwal, MD, MPH, discusses results from the phase 3 HARMONi trial, which were presented at IASLC World Conference on Lung Cancer. The randomized, double-blinded, placebo-controlled trial assessed the use of...
  • VIDEO: Recent studies ‘completely cement’ role of combination therapy in EGFR-mutated NSCLC
    Monday, October 27, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    In this video, Charu Aggarwal, MD, MPH, discusses OS data from the FLAURA2 trial, which were presented at IASLC World Conference on Lung Cancer. The trial assessed first-line osimertinib (Tagrisso, AstraZeneca) plus chemotherapy vs....
  • Marking Breast Cancer Awareness Month 2025, ESMO Calls for Increasing Awareness of the Cancer Risks Posed by Alcohol & the Development of Robust Policy Measures to Prevent Breast Cancer Cases
    Monday, October 27, 2025 from ESMO News
    With breast cancer being one of 7 types of cancer that carry increased risk due to alcohol consumption, it is pertinent that robust policy measures are taken at all political levels aimed at preventing breast cancer cases linked to alcohol.
  • FDA Approves Cemiplimab-rwlc for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma 
    Monday, October 27, 2025 from ESMO News
    Evidence for efficacy is based on the results from the C-POST study
  • Powered by Feed Informer